Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups

Katharine Yao*, Robert Goldschmidt, Mary Turk, Jelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of molecular subtyping using MammaPrint and BluePrint in women with early-stage breast cancer (BC) treated at US institutions following National Comprehensive Cancer Network standard guidelines. Tumor samples were collected from stage 1-2B consecutively diagnosed BC patients (n = 373) who underwent lumpectomy or mastectomy with an axillary staging procedure between 1992 and 2010 at two institutes (NorthShore University HealthSystem and Fox Chase Cancer Center) in the United States of America, with a median follow-up time of 9.5 years. MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk patients had a 10-year DMFS of 87 % (95 %CI 81.9–92.1) with a hazard ratio of 3.62 (95 %CI 1.38–9.50) (p = 0.005). Uni- and multivariate analyses included age, tumor size, grade, ER, and Her2; in multivariate analysis, MammaPrint reached near-significance (HR 3.01; p 0.08). When comparing BluePrint molecular subtyping with clinical stratification, the prognosis (10-year DMFS) was significantly different in 10-year DMFS between the different molecular subtypes (p < 0.001). This retrospective study with 10-year follow-up data provides valuable insight into prognosis of patients with primary BC comparing clinical with molecular subtyping. The BluePrint molecular stratification assay identifies patients with significantly different outcomes compared with standard clinical molecular stratification.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
JournalBreast Cancer Research and Treatment
Issue number1
StatePublished - Nov 1 2015


  • Breast cancer
  • Molecular assay
  • Molecular subtyping
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups'. Together they form a unique fingerprint.

Cite this